Clinical Trial Update: Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) [Phase 2]

View source ↗

Summary

Phase 2 trial of erenumab-aooe for temporomandibular disorders was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Temporomandibular Disorders

Drugs mentioned

• Erenumab-aooe (erenumab-aooe)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Temporomandibular Disorders | Phase 2 | Status: TERMINATED | Results posted: 2024-04-02